FOLH1 and prostate cancer: Agents targeting prostate-specific membrane antigen (PSMA) are under investigation for both imaging and therapy of prostate cancer [6, 7].[68Ga]Ga-PSMA-11 is currently under consideration for FDA approval in biochemically recurrent prostate cancer, and the phase 3 VISION trial evaluating safety and efficacy of [177Lu]Lu-PSMA-617 therapy is currently underway [8].